MRNS News and Press, Marinus Pharmaceuticals Inc. From 05/11/23

2023-05-11 07:07:12 ET Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q1 GAAP EPS of -$0.67 beats by $0.13 . Revenue of $10.38M (-26.8% Y/Y) beats by $5.47M . For the fiscal year 2023, the Company maintains its prior guidance with expected ZTALMY ...

ZTALMY ® (ganaxolone) first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023 CHMP opinion for ZTALMY in CDKL5 deficiency disorder expected by end of May; Eur...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. “With over 34 years of diverse commercial o...

2023-03-31 17:01:18 ET Marinus Pharma ( NASDAQ: MRNS ) disclosed in a Securities and Exchange filing on Friday a prospectus for a mixed shelf offering to raise up to $375 million. Under the offering, the company may sell common stock, preferred stock, debt securities, warrants...

2023-03-22 09:39:04 ET The U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to Marinus Pharmaceuticals' ( NASDAQ: MRNS ) ganaxolone to treat Lennox-Gastaut syndrome (LGS). LGS is a severe form of epilepsy which usually shows up during infa...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment ...

2023-03-07 22:04:10 ET Marinus Pharmaceuticals, Inc. (MRNS) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Vice President of Corporate Affairs and Investor Relations Scott Braunstein - Chairman and Chief Executive...

ZTALMY ® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022 Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2023 S...

2023-03-06 17:35:39 ET Marinus Pharmaceuticals ( NASDAQ: MRNS ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, after market close. The consensus EPS Estimate is -$0.75 (+2.6% Y/Y) and the consensus Revenue Estimate is $9.15M (+502.0% Y/Y). Over the...